New approaches in the treatment of HIV/AIDS - Focus on maraviroc and other CCR5 antagonists

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 473-485

  Schlecht, Hans P ^a   Schellhorn, Sarah ^b   Dezube, Bruce J ^b   Jacobson, Jeffrey M ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CCR5; Chemokine receptor; Coreceptor; HIV 1 tropism; Maraviroc; Viral entry

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 8 [4 (2 BUTOXYETHOXY)PHENYL] 1,2,3,4 TETRAHYDRO 1 ISOBUTYL N [4 (1 PROPYL 1H IMIDAZOL 5 YLMETHYLSULFINYL)PHENYL] 1 BENZAZOCINE 5 CARBOXAMIDE; ANTIVIRUS AGENT; APLAVIROC; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 MONOCLONAL ANTIBODY 004; COMBIR; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GSK 873140; INTEGRASE; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; ONI 4128; PLACEBO; PRO 140; TIPRANAVIR; UK 427587; VICRIVIROC; VIRUS ENZYME; VIRUS GLYCOPROTEIN; ZIDOVUDINE;

ABNORMAL DREAMING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOCARCINOMA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ASTHENIA; BRONCHITIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE MUTATION; GINGIVITIS; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; INJECTION SITE REACTION; LYMPHOMA; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; NOSE INFECTION; PHARYNGITIS; PROTEIN FUNCTION; PROTEIN VARIANT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS ENTRY; VIRUS LOAD;

EID: 44049089377     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Anderson J, Akkina R. 2007. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther, 14:1287-97.
2. Baba M, Nishimura O, Kanzaki N, et al. 1999. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA, 96:5698-703.
3. Baba M, Takashima K, Miyake H, et al. 2005. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother, 49:4584-91.
4. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1-1-1 infected adults. 2001. AIDS, 15:1369-77.
5. Blanpain C, Migeotte I, Lee B, et al. 1999. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood, 94:1899-905.
6. Brumme ZL, Goodrich J, Mayer RB, et al. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naïve individuals. J Infect Dis, 192:466-74.
7. Chan DC, Fass D, Berger JM, et al. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell, 89:263-73.
8. Chan DC, Kim PS. 1998. HIV entry and its inhibition. Cell, 93:681-4.
9. Coakley E, Petropoulos CJ, Whitcomb JM. 2005. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis, 18:9-15.
10. Cocchi F, DeVico AL, Garzino-Demo A, et al. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science, 270:1811-15.
11. Connor RI, Sheridan KE, Ceradini D, et al. 1997. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med, 185:621-8.
12. Cooper D, Gatell J, Rockstroh J, et al. 2007. Results from BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, Abstract 105aLB.
13. Crabb C. 2006. GlaxoSmithKline ends aplaviroc trials. AIDS, 20:641.
14. Daar ES, Kesler KL, Petropoulos CJ, et al. 2007. Hemophilia Growth and Development Study. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis, 45:643-9.
15. Dalgleish AG, Beverley PC, Clapham PR, et al. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 312:763-7.
16. Dean M, Carrington M, Winkler C, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science, 273:1856-62.
17. Deeks SG. 2006. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients. Lancet, 367:711-3.
18. Dorr P, Westby M, Dobbs S, et al. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother, 49:4721-32.
19. Dragic T, Litwin V, Allaway GP, et al. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature, 381:667-73.
20. Dragic T, Trkola A, Thompson DA, et al. 2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA, 97:5639-44.
21. Eckert DM, Kim PS. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem, 70:777-810.
22. Fätkenheuer G, Pozniak AL, Johnson MA, et al. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med, 11:1170-2.
23. Fischereder M, Luckow B, Hocher B, et al. 2001. CC chemokine receptor 5 and renal-tranplant survival. Lancet, 357:1758-61.
24. Galvani AP, Slatkin M. 2003. Evaluating plague and smallpox as historical selective pressures for the CCR5-Δ32 HIV-resistance allele. Proc Natl Acad Sci USA, 100:15276-9.
25. Glass WG, McDermott DH, Lim JK, et al. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med, 203:35-40.
26. Goetz MB, Leduc R, Kostman JR, et al. 2007. Prediction of disease progression by HIV coreceptor tropism in persons with untreated chronic HIV infection. Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill. Abstract H-1027.
27. Goodrich JM, Saag M, van der Ryst E, et al. 2007. 48-week safety and efficacy of maraviroc, a novel ccr5 antagonist, in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced patients infected with dual/mixed-tropic HIV-1. Program and abstracts of the 45th Annual Infectious Diseases Society of America, San Diego, CA, Abstract LB-2.
28. Greaves W, Landovitz R, Fätkenheuer G, et al. 2006. Late Virologic breakthrough in treatment-naive patients on a regimen of combivir + vicriviroc. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, Abstract 161LB.
29. Gulick R, Su Z, Flexner C, et al. 2007a. Phase II study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects: ACTG 5211. J Infect Dis, 196:304-12.
30. Gulick R, Su Z, Flexner C, et al. for the ACTG 5211 Team. 2007b. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results. Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, Abstract TUAB102.
31. Gulick R, Haas D, Collier A, et al. 2007c. Two-year follow-up of treatment-experienced patients on vicriviroc (VCV). Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstract H-1030.
32. Gulick RM, van der Ryst E, Lampiris H, et al. 2007d. Efficacy safety once-daily (QD) compared with twice-daily (BID) maraviroc plus optimized background therapy (OBT) in treatment-experienced patients infected with CCR5-tropic-HIV-1: 24-week combined analysis of the MOTIVATE 1 and 2 studies. Program and abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Abstract WEPEB116LB.
33. Guo Q, Ho HT, Dicker I, et al. 2003. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol, 77:10528-36.
34. Hammer SM, Saag MS, Schechter M, et al. 2006. International AIDS Society-USA panel. Treatment for adult HIV-1 infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA, 296:827-43.
35. Hartley O, Gaertner H, Wilken J, et al. 2004. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA, 101:16460-5.
36. Holmberg SD, Hamburger EM, Moorman AC, et al. 2003. Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. Clin Infect Dis, 37:702-7.
37. Huang Y, Paxton WA, Wolinsky SM, et al. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med, 2:1240-3.
38. Jacobson JM, Israel RJ, Lowy I, et al. 2004. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother, 48:423-9.
39. Jacobson JM, Thompson M, Saag MS, et al. 2007. Antiretroviral Activity and Pharmacodynamics of PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Individuals. Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstract H-716.
40. Ji C, Zhang J, Dioszegi M, et al. 2007. CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. Mol Pharmacol, 72:18-28.
41. Jouvenot Y, Perez E, Urnov FD, et al. 2005. Towards Gene Knock Out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs). Program and abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, Abstract H-1084.
42. Kadow J, Wang HG, Lin PF. 2006. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr Opin Investig Drugs, 7:721-6.
43. Koot M, Keet IP, Vos AH, et al. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med, 118:681-8.
44. Kuhmann SE, Pugach P, Kunstman KJ, et al. 2004. Genetic and phenotypic analyses of human immunodeficiency virus type I escape from a small-molecule CCR5 inhibitor. J Virol, 78:2790-807. Erratum in: J Virol, 2005. 78:6706.
45. Kwong PD, Wyatt R, Robinson J, et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature, 393:648-59.
46. Lalezari J, Thompson M, Kumar P, et al. 2005. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS, 19:1443-8.
47. Lalezari J, Lederman M, Yadavalli G, et al. 2006. A phase 1, dose-escalation, placebo-controlled study of a fully human monoclonal antibody (CCR5mAb004) against CCR5 in patients with CCR5-tropic HIV-1 infection. Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Abstract H-1668.
48. Lalezari J, Goodrich J, DeJesus F, et al. 2007. MOTIVATE 1. USA and Canada. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of phase 2b/3 studies. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, Abstract 104bLB.
49. Lapidot T. 2001. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann NY Acad Sci, 938:83-95.
50. Liu R, Paxton WA, Choe S, et al. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86:367-77.
51. Luther SA, Cyster JG. 2001. Chemokines as regulators of T cell differentiation. Nat Immunol, 2:102-7.
52. Maeda K, Yoshimura K, Shibayama S, et al. 2001. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem, 276:35194-200.
53. Maeda K, Nakata H, Koh Y, et al. 2004. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol, 78:8654-62.
54. Mani M, Kandavelou K, Dy FJ, et al. 2005. Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun, 335:447-57.
55. Markowitz M, Mohri H, Mehandru S, et al. 2005. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet, 365:1031-8.
56. Marozsan AJ, Kuhmann SE, Morgan T, et al. 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology, 338:182-99.
57. Melby T, Despirito M, Demasi R, et al. 2006. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis, 194:238-46.
58. Mocroft A, Phillips AN, Friis-Moller N, et al. 2002. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA Study. Antivir Ther, 1:21-30.
59. Mori J, Mosley M, Lewis M, et al. 2007. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2. Program and abstracts of the 16th International HIV Drug Resistance Workshop, Barbados, West Indies. Abstract 10.
60. Mosley M, Smith-Burchnell C, Mori J, et al. 2006. Resistance to the CCR5 antagonist maraviroc is characterized by dose-response curves that display a reduction in maximal inhibition. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado. Abstract 598.
61. Moyle GJ, Wildfire A, Mandalia S, et al. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis, 191:866-72.
62. Moyle GJ, DeJesus E, Boffi to M, et al. 2007. CXCR4 antagonism: proof of activity with AMD11070. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, Abstract 511.
63. Murga JD, Franti M, Pevear DC, et al. 2006. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother, 50:3289-96.
64. Nakata H, Maeda K, Miyakawa T, et al. 2005. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCRS antagonist, AK602/ ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. J Virol, 79:2087-96.
65. Nelson M, Fatkenheuer G, Konourina I, et al. 2007. MOTIVATE 2. Europe, Australia and USA. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of phase 2b/3 studies. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, Abstract 104aLB.
66. Oldfield V, Keating GM, Plosker G. 2005. Enfuvirtide: a review of its use in the management of HIV infection. Drugs, 65:1139-60.
67. Olson WC, Rabut GE, Nagashima KA, et al. 1999. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol, 735:4145-55.
68. Oppermann M. 2004. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal, 16:1201-10.
69. Palella FJ Jr, Delaney KM, Moorman AC, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV-1 Outpatient Study Investigators. N Engl J Med, 338:853-60.
70. Pastore C, Nedellec R, Ramos A, et al. 2006. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol, 80:750-8.
71. Philpott SM. 2003. HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res, 1:217-27.
72. Prahalad S. 2006. Negative association between the chemokine receptor CCR5-[Delta]32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun, 7:264-8.
73. Pugach P, Marozsan AJ, Ketas TJ, et al. 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology, 361:212-28.
74. Qin XF, An DS, Chen IS, et al. 2003. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA, 100:183-8.
75. Reynes J, Rouzier R, Kanouni T, et al. 2002. SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1-infected subjects. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, Abstract 1.
76. Roschke V, Clark S, Branco L, et al. 2004. Characterization of a panel of novel human monoclonal antibodies that specifically antagonize CCR5 and Block HIV-1 entry. Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., Abstract #2871.
77. Ruffing N, Sullivan N, Sharmeen L, et al. 1998. CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. Cell Immunol, 189:160-8.
78. Saag M, Ive P, Heera J, et al. 2007. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/ lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48 results of the MERIT study. Program and abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, Abstract WESS104.
79. Sabeti PC, Walsh E, Schaffner SF, et al. 2005. The case for selection at CCR5-Delta32. PLoS Biol, 3:e378.
80. Samson M, Libert F, Doranz BJ, et al. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 382:722-5.
81. Schooley RT, Mellors JW. 2007. No cure yet for HIV-1-1, but therapeutic research presses on. J Infect Dis, 195:770-2.
82. Schurmann D, Fätkenheuer G, Reynes J, et al. 2007. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS, 21:1293-9.
83. Shet A, Berry L, Mohri H, et al. 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1-1: a decade of experience. J Acquir Immune Defic Syndr, 41:439-46.
84. Signoret N, Hewlett L, Wavre S, et al. 2005. Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent. Mol Biol Cell, 16:902-17.
85. Simmons G, Clapham PR, Picard L, et al. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science, 276:276-9.
86. Starr-Spires LD, Collman RG. 2002. HIV-1 entry and entry inhibitors as therapeutic agents. Clin Lab Med, 22:681-701.
87. Steigbigel R, Kumar P, Eron J, et al. 2007. Results from BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, Abstract 105bLB.
88. Stephens JC, Reich DE, Goldstein DB, et al. 1998. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet, 62:1507-15.
89. Strizki JM, Xu S, Wagner NE, et al. 2001. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA, 98:12718-23.
90. Strizki JM, Tremblay C, Xu S, et al. 2005. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother, 49:4911-9.
91. Takashima K, Miyake H, Kanzaki N, et al. 2005. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother, 49:3474-82.
92. Thio CL, Astemborski J, Bashirova A, et al. 2007. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol, 81:441-5.
93. Tsamis F, Gavrilov S, Kajumo F, et al. 2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol, 77:5201-8.
94. Tsibris AMN, Gulick RM, Su Z, et al. 2007. In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc: findings from ACTG A5211. Program and abstracts of the 16th International HIV Drug Resistance Workshop, Barbados, West Indies, Abstract 13.
95. Unutmaz D, KewalRamani VN, Littman DR. 1998. G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions an on the utility of animal models. Semin Immunol, 10:225-36.
96. van der Ryst E, Westby M. 2007. Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc Motivate 1 and 2 clinical trials. Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstract H-715.
97. Walensky RP, Paltiel AD, Losina E, et al. 2006. The survival benefits of AIDS treatment in the United States. J Infect Dis, 194:11-9.
98. Westby M, Lewis M, Whitcomb J, et al. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol, 80:4909-20.
99. Westby M, Smith-Burchnell C, Mori J, et al. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol, 81:2359-71.
100. Wilkin TJ, Su Z, Kuritzkes DR, et al. 2007. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. J Infect Dis, 44:591-5.
101. Wong MM, Fish EN. 2003. Chemokines: attractive mediators of the immune response. Semin Immunol, 15:5-14.
102. Wood A, Armour D. 2005. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem, 43:239-71.
103. Zhao J, Ma L, Wu YL, et al. 1998. Chemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitization. J Cell Biochem, 71:36-45.